SCHEDULE: Jeffrey David Weiner Discloses Psyence Biomedical Stake

Jeffrey David Weiner has filed a Schedule 13G, reporting beneficial ownership of 59,750 shares, representing 2.61% of Psyence Biomedical Ltd.'s common stock.

Summary

• Jeffrey David Weiner has filed a Schedule 13G, indicating a beneficial ownership of 59,750 shares of Psyence Biomedical Ltd. common stock.
• This ownership stake represents 2.61% of the total outstanding shares of the company.
• The filing was made on June 9, 2026, and is an amendment to a previous filing.
• Weiner holds sole voting power and sole dispositive power over these shares.
• The filing asserts that these securities were not acquired or held for the purpose of influencing the control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial information about the company.

Positives

• Jeffrey David Weiner has disclosed a significant ownership stake, providing transparency to the market.
• The ownership of 2.61% indicates a notable interest in Psyence Biomedical Ltd.

Risks

• The filing does not detail any specific risks associated with the ownership stake or the company's operations.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant institutional or individual investors and do not inherently signal a change in company strategy or performance, but rather a change in ownership reporting.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes can influence investor confidence and market perception.
• Management: The certification by Weiner suggests no intent to influence control, which is a standard assurance for such filings.

Key Dates

Keywords

Psyence Biomedical Ltd., Schedule 13G, Beneficial Ownership, Common Shares, Jeffrey David Weiner, SEC Filing, Shareholder Disclosure